How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Prenatal Screening Market
- By Screening Technique: Non-Invasive Prenatal Testing (NIPT), Ultrasound Screening, Maternal Serum Screening, Chorionic Villus Sampling (CVS), Amniocentesis
- By Target Condition: Chromosomal Abnormalities, Neural Tube Defects, Genetic Disorders, Congenital Heart Defects, Other Structural Anomalies
- By End User: Hospitals, Diagnostic Laboratories, Specialty Clinics, Maternity Centers, Ambulatory Surgical Centers
- By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), Microarray Analysis, Mass Spectrometry
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Non-Invasive Prenatal Testing (NIPT) leads By Screening Technique at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Prenatal Screening Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Screening Technique 5
Target Condition 5
End User 5
Technology 5
Companies profiled
Roche Diagnostics
Illumina Inc.
Natera Inc.
Myriad Genetics Inc.
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings (LabCorp)
PerkinElmer Inc.
BGI Genomics
F. Hoffmann-La Roche AG
Agilent Technologies Inc.
Bio-Rad Laboratories Inc.
Invitae Corporation
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Natera Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Myriad Genetics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Quest Diagnostics Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Laboratory Corporation of America Holdings (LabCorp)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →PerkinElmer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →BGI Genomics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Agilent Technologies Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bio-Rad Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Invitae Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Thermo Fisher Scientific Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →SeraCare Life Sciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sema4
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,976M by 2033 · 10.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Non-Invasive Prenatal Testing (NIPT)54.9
- Ultrasound Screening8.3
- Maternal Serum Screening13.6
- Chorionic Villus Sampling (CVS)15.0
- Amniocentesis8.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$760.8M → $1,841M · 11.7%
Europe$530.3M → $1,045M · 8.9%
Asia Pacific$484.2M → $951.8M · 8.8%
Latin America$299.7M → $670.9M · 10.6%
Middle East and Africa$230.5M → $529.8M · 11.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.062026
10.062027
10.082028
10.072029
10.092030
10.102031
10.122032
10.132033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Diagnostics8.9
- Illumina Inc.17.9
- Natera Inc.9.9
- Myriad Genetics Inc.12.4
- Quest Diagnostics Incorporated10.3
- Laboratory Corporation of America Holdings (LabCorp)12.5
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Screening Technique28.4%
Target Condition31.6%
End User17.6%
Technology22.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.5
- Europe20.7
- Asia Pacific18.9
- Latin America13.3
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Diagnostics | 75 | 93 | 89 | 83 | 83 | 80 | 84 |
| Illumina Inc. | 90 | 79 | 91 | 90 | 69 | 72 | 82 |
| Natera Inc. | 68 | 66 | 85 | 84 | 88 | 76 | 78 |
| Myriad Genetics Inc. | 58 | 60 | 60 | 80 | 79 | 69 | 68 |
| Quest Diagnostics Incorporated | 64 | 75 | 68 | 74 | 69 | 64 | 69 |
| Laboratory Corporation of America Holdings (LabCorp) | 49 | 49 | 69 | 63 | 58 | 52 | 57 |
| PerkinElmer Inc. | 64 | 58 | 57 | 63 | 54 | 55 | 59 |
| BGI Genomics | 58 | 60 | 55 | 55 | 43 | 47 | 53 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Diagnostics
- Illumina Inc.
- Natera Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Diagnostics | ✓ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Illumina Inc. | ✓ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Natera Inc. | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Myriad Genetics Inc. | − | ◐ | ◐ | ✓ | ✓ | ✓ |
| Quest Diagnostics Incorporated | ✓ | ✓ | ◐ | ◐ | ◐ | − |
| Laboratory Corporation of America Holdings (LabCorp) | − | − | − | − | ◐ | − |
| PerkinElmer Inc. | − | ◐ | ◐ | ◐ | − | ◐ |
| BGI Genomics | − | − | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Diagnostics84
2Illumina Inc.82
3Natera Inc.78
4Quest Diagnostics Incorporated69
5Myriad Genetics Inc.68
6PerkinElmer Inc.59
7Laboratory Corporation of America Holdings (LabCorp)57
8BGI Genomics53
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Roche DiagnosticsIllumina Inc.Natera Inc.
Challenger2
Strong scale, closing on the leaders.
Myriad Genetics Inc.Quest Diagnostics Incorporated
Contender2
Focused players with pockets of strength.
Laboratory Corporation of America Holdings (LabCorp)PerkinElmer Inc.
Niche1
Specialists in a single segment or region.
BGI Genomics
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Screening Technique in North America, then scale across Prenatal Screening Market — a $569M beachhead inside a $8.75B market.
Beachhead (SOM)$569Mobtainable near-term
Serviceable (SAM)$3.32Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Non-Invasive Prenatal Testing (NIPT)
Best fit — highest urgency & budget in Screening Technique.
Economic buyer80 fit
Ultrasound Screening
Strong fit — clear ROI and a fast path to value.
End user65 fit
Maternal Serum Screening
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Screening Technique in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Condition & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel30%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Screening Technique leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Prenatal Screening Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified24%
Evaluation14%
Closed-won7%
$16.4KCAC
$73KLTV
4.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Prenatal Screening Market is a resilient opportunity — $975M by 2033, compounding at 3.3%.
TAM · 2025$754Mtoday
TAM · 2033$975Mforecast
CAGR3.3%2027–2033
Cumulative$7.74Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$975MTotal addressable market
SAM$374MServiceable available market
SOM$71MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.3% CAGR
Demand compounds through 2033, outpacing GDP across Screening Technique.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Screening Technique moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$975MLarge & growingTAM by 2033 at 3.3% CAGR
$374MServiceable nowreachable with today’s model
$71MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$760MBear2.1% CAGR
$975MBase3.3% CAGR
$1.25BBull4.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Condition optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Prenatal Screening Market — a $6.55B market by 2033. Plan: grow share from 6.6% to 12.7%.
Market size · 2033$6.55Btotal addressable
Market CAGR3.5%2027–2033
Target share12.7%from 6.6% today
Revenue ambition$832Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.6% | 12.7% | On track |
| Revenue | $410M | $832M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 37.2% | 39.4% | Ahead |
| Customer retention | 88.6% | 92.9% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Screening Technique
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Target Condition capability
A defensible second engine — invest in Target Condition to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Screening Technique share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Condition
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $107M capacity & capability investment
- Greenlight bolt-on M&A in Target Condition
- Authorise North America expansion plan
- Fund R&D program for Screening Technique leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Prenatal Screening Market conversation — a $5.64B market you can size, segment and defend in minutes.
Market size · 2033$5.64Btotal opportunity
Growth7.2%CAGR to 2033
Addressable buyers1,651+accounts in scope
Typical ROI7.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Screening Technique
Goal Grow share in Screening Technique
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.1×return on cost, year one
< 3 mopayback period
$100K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Roche DiagnosticsIllumina Inc.Natera Inc.Myriad Genetics Inc.Quest Diagnostics IncorporatedLaboratory Corporation of America Holdings (LabCorp)PerkinElmer Inc.BGI Genomics+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Prenatal Screening Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Prenatal Screening Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Automated Patient Appointment Reminder Software Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportMental Health Software Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportMedical Enterprise Data Storage Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportSingle Nucleotide Polymorphism (SNP) Genotyping Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportAutomated Insulin Delivery Systems Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportAlternative Drug Delivery Systems Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportAdvanced Clinical Research Information Systems Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportHuman Services Software Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportPulmonology Software Market
Market size, share, segmentation and regional forecast.
$391M market · 2025 base year
View reportPatient Data Management Systems Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View report5-Fluorosalicylic Acid Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View report5-Fluorocytosine (5-FC) Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.